ReviewOncogene2008
Immune escape as a fundamental trait of cancer: focus on IDO.
Review in Oncogene, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
159 citing papers in PubMed, 324 citations in OpenAlex.
- IDO1 Silencing Enhances Cisplatin Sensitivity in Gastric Cancer Cells via Modulation of Apoptosis and Oxidative Stress.Current issues in molecular biology · 2026Article
- Quercetin inhibits gastric cancer cell proliferation and migration and is associated with the suppression of the IDO1-Kynurenine-AhR axis.BMC cancer · 2025Article
- The integrative genomic and functional immunological analyses of colorectal cancer initiating cells to modulate stemness properties and the susceptibility to immune responses.Journal of translational medicine · 2025Article
- Spatial interaction mapping of PD-1/PD-L1 in head and neck cancer reveals the role of macrophage-tumour barriers associated with immunotherapy response.Journal of translational medicine · 2025Article
- Bibliometric analysis of traditional Chinese medicine in cancer treatment via immune system modulation (2015-2025).Frontiers in immunology · 2025Article
- Article
- Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia.Nature communications · 2024Article
- Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors.ImmunoTargets and therapy · 2024Review
- From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer.Frontiers in immunology · 2024Review
- The Functions and Mechanisms of Long Non-coding RNA SNHGs in Gastric Cancer.Combinatorial chemistry & high throughput screening · 2024Review
- Hormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor Immunity.International journal of molecular sciences · 2023Review
- A novel immunogenomic classification for prognosis in non-small cell lung cancer.Journal of cancer research and clinical oncology · 2023Article
- Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials.British journal of cancer · 2023Review
- The recent progress of myeloid-derived suppressor cell and its targeted therapies in cancers.MedComm · 2023Review
- Cellular nanovesicles for therapeutic immunomodulation: A perspective on engineering strategies and new advances.Acta pharmaceutica Sinica. B · 2023Review
- Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment.Journal of advanced research · 2023Article
- Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers.Molecular cancer · 2023Review
- Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy.Pharmaceutics · 2023Review
- IDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammation.Frontiers in oncology · 2023Review
- The role of mesenchymal stem cells derived exosomes as a novel nanobiotechnology target in the diagnosis and treatment of cancer.Frontiers in bioengineering and biotechnology · 2023Review
99 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Immune escape is a critical gateway to malignancy. The emergence of this fundamental trait of cancer represents the defeat of immune surveillance, a potent, multi-armed and essential mode of cancer suppression that may influence the ultimate clinical impact of an early stage tumor. Indeed, immune escape may be a central modifier of clinical outcomes, by affecting tumor dormancy versus progression, licensing invasion and metastasis and impacting therapeutic response. Although relatively little studied until recently, immune suppression and escape in tumors are now hot areas with clinical translation of several new therapeutic agents already under way. The interconnections between signaling pathways that control immune escape and those that control proliferation, senescence, apoptosis, metabolic alterations, angiogenesis, invasion and metastasis remain virtually unexplored, offering rich new areas for investigation. Here, an overview of this area is provided with a focus on the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDO) and its recently discovered relative IDO2 that are implicated in suppressing T-cell immunity in normal and pathological settings including cancer. Emerging evidence suggests that during cancer progression activation of the IDO pathway might act as a preferred nodal modifier pathway for immune escape, for example analogous to the PI3K pathway for survival or the VEGF pathway for angiogenesis. Small molecule inhibitors of IDO and IDO2 heighten chemotherapeutic efficacy in mouse models of cancer in a nontoxic fashion and an initial lead compound entered phase I clinical trials in late 2007. New modalities in this area offer promising ways to broaden the combinatorial attack on advanced cancers, where immune escape mechanisms likely provide pivotal support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.